Antonio Naranjo1, Soledad Ojeda-Bruno2, Ana Bilbao Cantarero2, Juan Carlos Quevedo Abeledo2, Luis Alberto Henríquez-Hernández3, Carlos Rodríguez-Lozano2. 1. Servicio de Reumatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España; Departamento de Ciencias Médicas y Quirúrgicas, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España. Electronic address: anarher@gobiernodecanarias.org. 2. Servicio de Reumatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España. 3. Departamento de Ciencias Clínicas, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España; Servicio de Oncología Radioterápica, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
Abstract
OBJECTIVE: To assess the influence of the implementation of a program for secondary prevention of osteoporotic fractures on prescribing bisphosphonates and persistent short-term treatment. PATIENTS AND METHODS: Patients >50 years with fragility fracture attended in the emergency department were enrolled in an observational study. The program consisted of: 1) training of primary care physicians, 2) baseline visit: questionnaire on osteoporosis, bone densitometry and patient education, 3) patient referral to primary care, except those with multiple fractures or requiring special study or therapy, who were referred to a specialist, and 4) follow-up by checking prescriptions in electronic records, and a telephone survey. The outcome variable was the percentage of patients who, on having been prescribed bisphosphonates, still adhered to the treatment at 3 months. RESULTS: Of the 532 patients with inclusion criteria, 202 (39%) refused to participate. Those who refused to take part had a higher mean age (P<.01) and a higher frequency of hip fracture (P<.01) compared with patients who did participate. A total of 330 patients were included for intervention, with a mean age of 71 years, and 254(77%) were female. An antiresorptive was being used by 45 patients (13%) at baseline. After the baseline visit 223 patients (67%) were recommended a bisphosphonate. In the follow-up at 3 months 78% of patients who had been prescribed bisphosphonate were still receiving treatment. CONCLUSIONS: We present a multidisciplinary program for secondary prevention of fractures coordinated by rheumatology in which the number of patients who were receiving bisphosphonate at 3 months increased by four times compared to baseline visit.
OBJECTIVE: To assess the influence of the implementation of a program for secondary prevention of osteoporotic fractures on prescribing bisphosphonates and persistent short-term treatment. PATIENTS AND METHODS: Patients >50 years with fragility fracture attended in the emergency department were enrolled in an observational study. The program consisted of: 1) training of primary care physicians, 2) baseline visit: questionnaire on osteoporosis, bone densitometry and patient education, 3) patient referral to primary care, except those with multiple fractures or requiring special study or therapy, who were referred to a specialist, and 4) follow-up by checking prescriptions in electronic records, and a telephone survey. The outcome variable was the percentage of patients who, on having been prescribed bisphosphonates, still adhered to the treatment at 3 months. RESULTS: Of the 532 patients with inclusion criteria, 202 (39%) refused to participate. Those who refused to take part had a higher mean age (P<.01) and a higher frequency of hip fracture (P<.01) compared with patients who did participate. A total of 330 patients were included for intervention, with a mean age of 71 years, and 254(77%) were female. An antiresorptive was being used by 45 patients (13%) at baseline. After the baseline visit 223 patients (67%) were recommended a bisphosphonate. In the follow-up at 3 months 78% of patients who had been prescribed bisphosphonate were still receiving treatment. CONCLUSIONS: We present a multidisciplinary program for secondary prevention of fractures coordinated by rheumatology in which the number of patients who were receiving bisphosphonate at 3 months increased by four times compared to baseline visit.
Authors: A Naranjo; S Ojeda-Bruno; A Bilbao-Cantarero; J C Quevedo-Abeledo; B V Diaz-González; C Rodríguez-Lozano Journal: Osteoporos Int Date: 2015-06-06 Impact factor: 4.507
Authors: Lisanne Vranken; Caroline E Wyers; Joop P W van den Bergh; Piet P M M Geusens Journal: Calcif Tissue Int Date: 2017-05-24 Impact factor: 4.333
Authors: L Vranken; C E Wyers; R Y Van der Velde; H M Janzing; S Kaarsemaker; P P Geusens; J P Van den Bergh Journal: Osteoporos Int Date: 2017-11-23 Impact factor: 4.507
Authors: E Casado; J Blanch; C Carbonell; J C Bastida; J L Pérez-Castrillón; L Canals; L Lizán Journal: Arch Osteoporos Date: 2021-02-27 Impact factor: 2.617
Authors: Antonio Naranjo; Daniel Prieto-Alhambra; Julián Sánchez-Martín; Alejandro Pérez-Mitru; Max Brosa Journal: Clinicoecon Outcomes Res Date: 2022-04-22
Authors: A Naranjo; S Ojeda; M Giner; M Balcells-Oliver; L Canals; J M Cancio; E Duaso; J Mora-Fernández; C Pablos; A González; B Lladó; F J Olmo; M J Montoya; A Menéndez; D Prieto-Alhambra Journal: Arch Osteoporos Date: 2020-04-25 Impact factor: 2.617